13 October 2014

Designing Safer Medicines: What Works and What Doesn't

Organised by:

SCI’s Fine Chemicals Group

SCI, London, UK

Registration Closed

This event is no longer available for registration.

This meeting aims to provide practical insights into some of the recent improvements in this key area. It follows on from the success of the 'Designing Safer Medicines' meeting in 2011.
There is a clear need in drug development to reduce attrition from clinical studies especially due to toxicology. It was estimated that a 5-10% improvement in the attrition rate could double the output of marketed drugs and various preclinical approaches and strategies have been developed to help the chemist design safer medicines.

This meeting is targeted at all those who are involved in the lead identification and lead optimisation processes in Drug Discovery and those interested in furthering their knowledge of current and emerging approaches to designing better toxicology models and safer Drug Candidates.


Day 1

Registration and refreshments
Welcome and introduction
Reducing cardiovascular safety-related attrition: the good, the bad, the ugly and the future
Dr Chris Pollard, AstraZeneca
Screening strategies for Drug-Induced Liver Injury
Dr James Sidaway, Independant
In vivo models in safety and toxicity: cross-company data sharing to assess what works and what doesn't
Dr Kathryn Chapman, NC3Rs
Lunch and exhibition
Investigative approaches to address toxicological issues in drug discovery and development: case examples
Dr Monicah Otieno, Bristol-Myers Squibb
Designing in safer chemistry space; the use of multiparametric models in predicting drug safety
Dr Nigel Greene, Pfizer Worldwide Medicinal Chemistry
Early safety evaluation: combining polypharmacology predictions and network biology to prioritize experimental testing
Dr Cedric Merlot, LeadOp Computing
Big data analysis - application for designing safer drugs
Dr Edward J Griffen, MedChemica Ltd
Improving toxicity predictions to design safer acidic molecules
Dr Nigel Swain, Pfizer Worldwide Medicinal Chemistry
Influence of early safety science in drug discovery
Dr Mark Anderton, AstraZeneca
Closing remarks
Wine reception
Accessibility Grants

SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.

Venue and Contact


14/15 Belgrave Square
London SW1X 8PS


Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Early Bird Rate - before 29 August 2014

One-Day Fee Two-Day Fee*
SCI Member GB£100 SCI Member GB£175
SCI Student Member GB£35 SCI Student Member GB£60
Non-Member GB£130 Non-Member GB£235

Standard Rate - after 29 August 2014

One-Day Fee Two-Day Fee*
SCI Member GB£115 SCI Member GB£205
SCI Student Member GB£40 SCI Student Member GB£70
Non-Member GB£150 Non-Member GB£270

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations

Booking Process/Deadlines

For booking terms and conditions click here.

CPD Info

SCI Members attending this meeting are able to claim CPD points.

Accredited cpd Centre - The CPD Standards Office - CPD Provider 41057 - www.cpdstandards.com



Additional Info

Further Information and Sponsorship Opportunities

Discounts are available for dual registration with the 'Highlights in Medicinal Chemistry' meeting which will be run back-to-back with this meeting. 
For further information about sponsorship opportunities, please contact the conference team using the details provided below.